Literature DB >> 1779239

Cortical serotonin-S2 receptor binding in Lewy body dementia, Alzheimer's and Parkinson's diseases.

A V Cheng1, I N Ferrier, C M Morris, S Jabeen, A Sahgal, I G McKeith, J A Edwardson, R H Perry, E K Perry.   

Abstract

The binding of the selective 5-HT2 antagonist [3H]ketanserin has been investigated in the temporal cortex of patients with Alzheimer's disease (SDAT), Parkinson's disease (PD), senile dementia of Lewy body type (SDLT) and neuropathologically normal subjects (control). 5-HT2 binding was reduced in SDAT, PD with dementia and SDLT. SDAT showed a 5-HT2 receptor deficit across most of the cortical layers. A significant decrease in 5-HT2 binding in the deep cortical layers was found in those SDLT cases without hallucinations. SDLT cases with hallucinations only showed a deficit in one upper layer. There was a significant difference in cortical layers III and V between SDLT without hallucinations and SDLT with hallucinations. The results confirm an abnormality of serotonin binding in various forms of dementia and suggest that preservation of 5-HT2 receptor in the temporal cortex may differentiate hallucinating from non-hallucinating cases of SDLT.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1779239     DOI: 10.1016/0022-510x(91)90193-b

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN: 0022-510X            Impact factor:   3.181


  18 in total

1.  Advances in the treatment of visual hallucinations in neurodegenerative diseases.

Authors:  Daniel Collerton; John-Paul Taylor
Journal:  Future Neurol       Date:  2013-07

2.  Salsolinol, catecholamine metabolites, and visual hallucinations in L-dopa treated patients with Parkinson's disease.

Authors:  A Moser; F Siebecker; P Vieregge; P Jaskowski; D Kömpf
Journal:  J Neural Transm (Vienna)       Date:  1996       Impact factor: 3.575

3.  An immunohistochemical study of the serotonin 1A receptor in the hippocampus of subjects with Alzheimer's disease.

Authors:  Katsuyoshi Mizukami; Masanori Ishikawa; Hiroyasu Akatsu; Eric E Abrahamson; Milos D Ikonomovic; Takashi Asada
Journal:  Neuropathology       Date:  2011-01-27       Impact factor: 1.906

Review 4.  The neurobiological basis of cognitive impairment in Parkinson's disease.

Authors:  Glenda M Halliday; James B Leverenz; Jay S Schneider; Charles H Adler
Journal:  Mov Disord       Date:  2014-04-15       Impact factor: 10.338

5.  Focal atrophy in dementia with Lewy bodies on MRI: a distinct pattern from Alzheimer's disease.

Authors:  Jennifer L Whitwell; Stephen D Weigand; Maria M Shiung; Bradley F Boeve; Tanis J Ferman; Glenn E Smith; David S Knopman; Ronald C Petersen; Eduardo E Benarroch; Keith A Josephs; Clifford R Jack
Journal:  Brain       Date:  2007-01-31       Impact factor: 13.501

Review 6.  Genetics of psychosis in Alzheimer's disease: a review.

Authors:  Mary Ann DeMichele-Sweet; Robert A Sweet
Journal:  J Alzheimers Dis       Date:  2010       Impact factor: 4.472

Review 7.  The application of positron-emitting molecular imaging tracers in Alzheimer's disease.

Authors:  Robert M Cohen
Journal:  Mol Imaging Biol       Date:  2007 Jul-Aug       Impact factor: 3.488

Review 8.  Neuropsychiatric aspects of dementia with Lewy bodies.

Authors:  N Hirono; J L Cummings
Journal:  Curr Psychiatry Rep       Date:  1999-10       Impact factor: 5.285

Review 9.  The serotonergic system in motor and non-motor manifestations of Parkinson's disease.

Authors:  Philippe Huot; Susan H Fox
Journal:  Exp Brain Res       Date:  2013-06-28       Impact factor: 1.972

10.  Genetics of Psychosis in Alzheimer Disease.

Authors:  Mary Ann A DeMichele-Sweet; Robert A Sweet
Journal:  Curr Genet Med Rep       Date:  2014-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.